NIVF Stock Analysts Drive 400% Higher Price Targets to $76.50

Equity research teams tracking NewGenIvf Group have dramatically adjusted their 12-month price outlook, lifting consensus targets to $76.50 per share. This represents a striking 400% surge compared to the prior consensus of $15.30 established in mid-November 2025. The upward revision signals shifting analyst sentiment around the biotech company’s prospects.

Current target estimates range between $75.75 on the conservative end and $78.75 on the bullish end, with the consensus figure falling near the midpoint of this range. Notably, the collective $76.50 target implies a potential 5,175.86% move from the most recent trading price of $1.45 per share, underscoring the magnitude of the bullish sentiment among research teams.

Analyst Consensus Reflects 400% Sentiment Shift

The 400% elevation in price targets within a few months reveals significant reassessment by multiple analysts covering the stock. This dramatic adjustment typically reflects updated company performance data, sector dynamics, or strategic developments that warrant higher valuation expectations. The tight clustering of individual targets ($75.75-$78.75) suggests broad analyst agreement on the stock’s near-term trajectory despite the aggressive bull case.

Institutional Fund Positioning and Ownership Trends

Current institutional oversight of NIVF shows mixed signals. Three funds and investment institutions are actively reporting positions in the company, marking a 50% decrease from the prior quarter when six institutional holders were tracked. This quarter-over-quarter decline may suggest selective profit-taking or portfolio rebalancing among tracked funds.

Portfolio allocation to NIVF averaged 0.00% across all monitored funds—though this metric increased 84.29% compared to the previous quarter’s baseline. More significantly, total institutional share holdings contracted sharply by 96.90% over the three-month period, dropping to negligible levels. This contraction stands in contrast to the bullish analyst targets, potentially reflecting institutional wariness despite improving price targets.

Major Shareholders Currently Monitoring NIVF

SBI Securities Co. maintains a tracked position representing approximately 0.03% ownership stake in the company. Bank of America similarly holds shares representing 0.00% of outstanding equity. The modest institutional positioning—relative to the aggressive analyst targets—suggests that large financial institutions remain cautious, even as research teams upgrade their views significantly.

The divergence between bullish 400% analyst target revisions and declining institutional holdings warrants close monitoring as NIVF’s story continues to develop.